{"denomUnitsSelected":"Participants","description":"PFS was defined as time from randomization to progression or death. Progression is characterized by any of the following:\n\n* ≥ 50% increase from nadir since start of treatment (tx) in the sum of the products of ≥ 2 lymph nodes on 2 consecutive exams 2 weeks apart\n* ≥ 50% increase from nadir since start of tx in the size of liver and/or spleen\n* ≥ 50% increase in the absolute number of circulating lymphocytes not due to tumor flare reaction. The absolute lymphocyte count must be ≥ 5x10\\^9/L to qualify as progression.\n* Transformation to a more aggressive histology. For patients with a complete response or nodular partial response, progression is defined as recurrence of circulating leukemia cell clone in the peripheral blood and an absolute lymphocyte count \\> 5x10\\^9/L and/or recurrence of palpable lymphadenopathy \\>1.5 cm by physical exam.\n\nMRD status was evaluated at 2 years and samples with \\<=20 monotypic events or an MRD level of \\<10\\^-4 were classified as undetectable MRD.","reportingStatus":"NOT_POSTED","timeFrame":"Assessed every 3 months until progression up to 5 years","title":"Progression-free Survival (PFS) by Measurable Residual Disease (MDR) Status at 2 Years","type":"SECONDARY"}